The Schedule

8:30-9:00 Registration and breakfast

9:00-11:30 Two concurrent sessions

Session A (Lymphoma I)

9:00-10:00 The Witch is Dead…Throwing water on the role of autotransplant in patients w/ Mantle Cell Lymphoma

Tycel Phillips, MD, City of Home Comprehensive Cancer Center, Los Angeles, CA

CAR-T in Non Hodgkins Lymphoma  

Monalisa Ghosh, MD, Michigan Medicine, Division of Hematology Oncology

Ask the experts, Drs. Phillips and Ghosh: 10-15 minutes for questions/cases

Moderator, Yasmin Karimi, MD, Michigan Medicine, Division of Hematology Oncology

10:00-10:30 T-cell lymphomas: Deconstructing the NCCN guidelines

Ryan Wilcox, MD, PhD, Michigan Medicine, Division of Hematology Oncology

10:30-11:00    Updates in Hodgkin lymphoma treatment and the role of radiation

Kyle Cuneo, MD, Michigan Medicine, Radiation Oncology

Dahlia Sano, MD, Michigan Medicine,  Division of Hematology Oncology

11:00-11:30      High-risk CLL and Richter’s transformation

Sami Malek, MD, Michigan Medicine, Division of Hematology Oncology

Session B (MDS/AML/MPN/ALL)

9:00-10:00 Clinical controversies in acute leukemia 

Lydia Benitez, PharmD, BCOP, Michigan Medicine, Pharmacy

Patrick Burke, MD, Michigan Medicine, Division of Hematology Oncology

Bernard Marini, PharmD, BCOP, Michigan Medicine, Pharmacy

Anthony Perissinotti, PharmD, BCOP, Michigan Medicine, Pharmacy

10:00-10:20     Update in myelofibrosis

Moshe Talpaz, MD, Michigan Medicine, Division of Hematology Oncology

10:20-10:50     Clonal hematopoiesis

Morgan Jones MD, PhD, Michigan Medicine, Division of Hematology Oncology

10:50-11:20     ET/PV: New treatments on the horizon, but who needs treatment?

Kristen Pettit, MD, Michigan Medicine, Division of Hematology Oncology

11:30-12:30 Lunch available

12:00-1:00 Keynote Address 

Jennifer Woyach, MD

Professor and Director of the Division of Hematology

D Warren Brown Chair of Leukemia Research

Co-Director of the Leukemia Research Program, OSU Comprehensive Cancer Center

1:00-3:30 Two concurrent sessions

Session A (Lymphoma II)

1:00-2:00 Panel Discussion: Audience provided cases/questions

2:00-2:30 Diffuse Large B-Cell Lymphoma 

Yasmin Karimi, MD, Michigan Medicine, Division of Hematology Oncology

2:30-3:00 Immunodeficiency-associated NHL

Shannon Carty, MD, Michigan Medicine, Division of Hematology Oncology

3:00-3:30      Updates in Follicular Lymphoma  

Jonathan Weiss, MD, Michigan Medicine, Division of Hematology Oncology

Session B (Myeloma)

1:00-2:00 AL Amyloidosis: Beyond ANDROMEDA 

Jeffrey Zonder, MD, Karmanos Cancer Institute, Wayne State University

2:00-2:45        Where to Park the CAR?  Balancing Cell Therapy Response and Toxicity in  Multiple Myeloma 

Marcus Geer, MD, Michigan Medicine, Division of Hematology Oncology

2:45-3:30 Management of Multiple Myeloma in 2025: State of the Art 

Matthew Pianko, MD, Michigan Medicine, Division of Hematology Oncology